Nivolumab for treating advanced, unresectable or metastatic melanoma
Status Complete
Process STA
Referral date June 2015

Scoped as part of Batch 41


Key events during the development of the guidance:

Date Update
24 February 2016 Expected publication
18 February 2016 Guidance published
22 January 2016 - 05 February 2016 Final appraisal determination
August 2015

Following the CHMP positive opinion, the company met with the NICE team and proposed that the three scopes for nivolumab monotherapy (ID845, ID846 and ID847) could be combined into one Single Technology Appraisal (STA), with a second STA for nivolumab in combination with ipilimumab (ID848) to follow in line with the proposed license extension.

At the Decision Point 4 meeting, following the draft scope consultation and scoping workshop this approach was agreed.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance